« Back to Record
Citation APA

Bisogno, G., De Salvo, G. L., Bergeron, C., Gallego Melcón, S., Merks, J. H. M., Kelsey, A., Martelli, H., Minard-Colin, V., Orbach, D., Glosli, H., Chisholm, J., Casanova, M., Zanetti, I., Devalck, C., Ben-Arush, M., Mudry, P., Ferman, S., Jenney, M., & Ferrari, A. (2019). Vinorelbine and continuous low-dose cyclophosphamide as maintenance chemotherapy in patients with high-risk rhabdomyosarcoma (RMS 2005): a multicentre, open-label, randomised, phase 3 trial. Lancet oncology, 20(11), 1566-1575. doi:10.1016/S1470-2045(19)30617-5


Permalink

http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/297145

Bisogno, G., De Salvo, G. L., Bergeron, C., Gallego Melcón, S., Merks, J. H. M., Kelsey, A., Martelli, H., Minard-Colin, V., Orbach, D., Glosli, H., Chisholm, J., Casanova, M., Zanetti, I., Devalck, C., Ben-Arush, M., Mudry, P., Ferman, S., Jenney, M., & Ferrari, A. (2019). Vinorelbine and continuous low-dose cyclophosphamide as maintenance chemotherapy in patients with high-risk rhabdomyosarcoma (RMS 2005): a multicentre, open-label, randomised, phase 3 trial. Lancet oncology, 20(11), 1566-1575. doi:10.1016/S1470-2045(19)30617-5